🇺🇸 FDA
Patent

US 12098385

Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy

granted A61KA61K35/34A61K38/17

Quick answer

US patent 12098385 (Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy) held by The Regents of the University of California expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K35/34, A61K38/17, A61K38/177, A61K48/005